Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00278174
Recruitment Status : Completed
First Posted : January 18, 2006
Last Update Posted : May 4, 2011
National Cancer Institute (NCI)
Information provided by:
Case Comprehensive Cancer Center

January 16, 2006
January 18, 2006
May 4, 2011
February 2005
April 2007   (Final data collection date for primary outcome measure)
  • Safety
  • Efficacy
Not Provided
Complete list of historical versions of study NCT00278174 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer
A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma

RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer.

PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients with metastatic kidney cancer.



  • Determine the objective response rate in patients with metastatic renal clear cell carcinoma treated with interferon alfa-1b.


  • Determine the toxicity of this drug in these patients.

OUTLINE: This is an open-label study.

Patients receive interferon alfa-1b subcutaneously daily. Treatment continues in the absence of unacceptable toxicity or disease progression.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Kidney Cancer
Biological: recombinant interferon alpha-1b
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
April 2007
April 2007   (Final data collection date for primary outcome measure)


  • Histologically or cytologically confirmed predominantly renal clear cell carcinoma

    • Clinical evidence of OR biopsy-proven metastatic disease to a site or sites distant from the primary tumor
  • Must have measurable disease, defined as ≥ 1 unidimensionally measurable lesion measured as ≥ 20 mm with conventional techniques OR as ≥ 10 mm with spiral CT scan
  • Good- or intermediate-risk category as defined by having ≤ 2 of the following factors:

    • Time from initial diagnosis to treatment < 1 year
    • Karnofsky performance status < 80%
    • Hemoglobin < lower limit of normal
    • Corrected calcium > 10.0 mg/dL
    • Lactate dehydrogenase (LDH) > 1.5 times upper limit of normal (ULN)
  • No major clinical ascites or pleural effusion
  • No CNS metastases by neurologic exam and CT scan or MRI


  • ECOG performance status 0-1
  • Life expectancy ≥ 3 months
  • WBC ≥ 3,000/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9.5 g/dL
  • Creatinine ≤ 1.5 mg/dL (2.0 mg/dL in post-nephrectomy patients)
  • Calcium normal
  • Total bilirubin ≤ 1.5 mg/dL
  • AST ≤ 3.0 times normal
  • Alkaline phosphatase ≤ 2.5 times normal (10 times ULN in presence of bone metastases)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception prior to and for the duration of study treatment
  • No history of serious cardiac arrhythmia, congestive heart failure, angina pectoris, or other severe cardiovascular disease (i.e., New York Heart Association class III or IV)
  • No known positivity for HIV or hepatitis B surface antigen
  • No history of seizure disorders
  • No local and/or systemic infections requiring antibiotics within 28 days prior to study entry
  • No other malignancy except basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the uterine cervix, or any malignancy treated with curative intent and in complete remission for > 3 years


  • No prior organ allografts
  • No prior interferon
  • No prior cytokine-based therapy for metastatic disease
  • Prior radiotherapy is allowed for the control of pain from skeletal lesions provided treatment was completed > 28 days prior to study entry and patient has recovered
  • No major surgery requiring general anesthesia within 28 days prior to study entry
  • No more than 2 prior therapies for metastatic disease
  • No concurrent palliative radiotherapy
  • No concurrent chemotherapy
  • No concurrent hormonal therapy except for hormones administered for nondisease-related conditions (e.g., insulin for diabetes)
  • No concurrent steroid use except ongoing replacement therapy with physiologic doses of corticosteroids

    • No concurrent dexamethasone or other steroidal anti-emetics or anti-inflammatories
  • No other concurrent anticancer therapy
  • No concurrent aspirin or barbiturates
  • No other concurrent investigational agents
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
P30CA043703 ( U.S. NIH Grant/Contract )
CCF-7752 ( Other Identifier: Cleveland Clinic IRB )
CASE15804 ( Other Identifier: Case Comprehensive Cancer Center )
Not Provided
Not Provided
Ronald M. Bukowski, Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Study Chair: Ronald M. Bukowski, MD The Cleveland Clinic
Case Comprehensive Cancer Center
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP